Home example 2 - Pharmamarketeer

farma-industrie

Pfizer and Novartis partner up to develop combo therapies for NASH

Pfizer and Novartis are set to team up in a non-exclusive partnership aimed at the clinical development of one or more combo therapies for the treatment of non-alcoholic steatohepatitis (NASH). Under the partnership...

InPharm.com

3 x gelezen

wet- en regelgeving

Keytruda Gets FDA Approval for Hepatocellular Carcinoma

The approval was based on data from the KEYNOTE-224 study, a single-arm trial in patients with HCC who had disease progression on or after sorafenib or were intolerant to sorafenib; had measurable disease; and Child...

Monthly Prescribing Reference (MPR): Drug News

3 x gelezen

onderzoek

Phase 3 failure of asthma therapy sends Vectura’s ailing shares falling

Vectura has announced it is terminating development of its severe asthma therapy VR475, an inhaled formulation of the corticosteroid budesonide, after it failed in Phase 3 trials to demonstrate a significant impact on...

InPharm.com

3 x gelezen

farma-industrie

Roche’s Hemlibra stakes claim to be haemophilia market leader

Hemlibra was widely expected to become the dominant therapeutic for treating haemophilia patients and its latest clinical trial results only cements its prospects in the field.

Pharmafile

3 x gelezen

farma-industrie

J&J stock tumbles after Reuters reports it hid asbestos in talc

After a series of ups and downs in defense of its flagship Johnson’s Baby Powder, Johnson & Johnson hit renewed scrutiny Friday as Reuters reported the drugmaker knew for decades its powder contained cancer-causing...

FiercePharma

3 x gelezen

overig

‘Europese regels nodig over transparantie banden zorg en farma’

Het openbaar maken van financiële banden tussen zorgverleners en de farmaceutische industrie in Europa kan beter. Ook in Nederland is er nog onvoldoende transparantie, concluderen onderzoekers van universiteiten in...

Skipr

3 x gelezen

onderzoek

Roche pulls plug on Alzheimer’s drug after Phase 3 failure

Roche has announced that it is to terminate two Phase 3 studies investigating the efficacy of its anti-beta-amyloid molecule crenezumab in the treatment of early sporadic Alzheimer’s disease (AD), after it became...

InPharm.com

3 x gelezen

marketing

[column] Geïntegreerd merkdenken: van communicatie naar customer experience

Het laatste hoofdstuk van merkkroniek Brandr stond nog open voor extrapolatie naar het nu. Dit hiaat is nu opgevuld door hedendaagse merkdenkers. MarketingTribune presenteert deze reeks met als (voorlopige) slot-auteur:...

MarketingTribune

3 x gelezen

wet- en regelgeving

Soliris Gets Priority Review for Rare, Complement-Mediated CNS Disorder

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Soliris (eculizumab; Alexion) for use in patients with neuromyelitis optica spectrum...

Monthly Prescribing Reference (MPR): Drugs in the Pipeline

3 x gelezen

overig

EU-parlement stemt voor EMA in Amsterdam

De komst van het Europees Geneesmiddelenbureau (EMA) kan Nederland nagenoeg zeker niet meer ontglippen. Het Europees Parlement heeft de verhuizing van Londen naar Amsterdam goedgekeurd, op voorwaarde dat de autoriteiten...

Skipr

3 x gelezen

Latest articles

Pfizer and Novartis partner up to develop combo therapies for NASH

Keytruda Gets FDA Approval for Hepatocellular Carcinoma

Phase 3 failure of asthma therapy sends Vectura’s ailing shares falling

Roche’s Hemlibra stakes claim to be haemophilia market leader

J&J stock tumbles after Reuters reports it hid asbestos in talc

‘Europese regels nodig over transparantie banden zorg en farma’

Roche pulls plug on Alzheimer’s drug after Phase 3 failure

[column] Geïntegreerd merkdenken: van communicatie naar customer experience

Soliris Gets Priority Review for Rare, Complement-Mediated CNS Disorder

EU-parlement stemt voor EMA in Amsterdam

Wekelijkse highlights per e-mail

Algemene informatie